Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors

Jian-Guo Zhou, Anna-Jasmina Donaubauer, Benjamin Frey, Ina Becker, Sandra Rutzen, Markus Eckstein, Roger Sun, Hu Ma, Philipp Schubert, Claudia Schweizer, Rainer Fietkau, Eric Deutsch, Udo Gaipl, Markus Hecht

ABSTRACT

Background The predictive power of novel biological markers for treatment response to immune checkpoint inhibitors (ICI) is still not satisfactory for the majority of patients with cancer. One should identify valid predictive markers in the peripheral blood, as this is easily available before and during treatment. The current interim analysis of patients of the ST-ICI cohort therefore focuses on the development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with metastatic cancer to ICI targeting the programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) axis.

Methods A total of 104 patients were prospectively enrolled. 54 immune cell subsets were prospectively analyzed in patients’ peripheral blood by multicolor flow cytometry before treatment with ICI (pre-ICI; n=89), and after the first application of ICI (n=65). Pre-ICI, patients were randomly allocated to a training (n=56) and a validation cohort (n=33). Univariate Cox proportional hazards regression analysis and least absolute shrinkage and selection operator Cox model were used to create a predictive immune signature, which was also checked after the first ICI, to consider the dynamics of changes in the immune status.

Results Whole blood samples were provided by 89 patients pre-ICI and by 65 patients after the first ICI. We identified a LIPS which is based on five immune cell subtypes: CD14+CD16+ monocytes, CD8+/PD-1+ T cells, plasmacytoid dendritic cells, neutrophils, and CD3+/CD56+/CD16+ natural killer (NKT) cells. The signature achieved a high accuracy (C-index 0.74 vs 0.71) for predicting overall survival (OS) benefit in both the training and the validation cohort. In both cohorts, the low-risk group had significantly longer OS than the high-risk group (HR 0.26, 95% CI 0.12 to 0.56, p=0.00025; HR 0.30, 95% CI 0.10 to 0.91, p=0.024, respectively). Regarding the whole cohort, LIPS also predicted progression-free survival (PFS). The identified LIPS was not affected by clinicopathological features with the exception of brain metastases. NKT cells and neutrophils of the LIPS can be used as dynamic predictive biomarkers for OS and PFS after first administration of the ICI.

Conclusion Our study identified a predictive LIPS for survival of patients with cancer treated with PD-1/PD-L1 ICI, which is based on immune cell subsets in the peripheral whole blood.

Trial registration number NCT03453892.

INTRODUCTION

Immune checkpoint inhibitors (ICI) can effectively restore the activity of exhausted CD8+ cytotoxic T cells and thereby trigger antitumor immune responses. During the last years, several ICI were approved for more than ten different tumor entities. However, still only the minority of patients shows durable responses. In clinical trials, the expression of programmed cell death-ligand 1 (PD-L1) on tumor and/or immune cells has been frequently used to select patient subgroups with higher chances of treatment response. However, the predictive power of PD-L1 expression is restricted and its expression varies, as its expression is for example increased after radiotherapy. Consequently, large effort has been made to identify routinely available blood and clinical markers that may predict the response to ICI therapies, besides and complementary to the analyzes of genomic instability. The latter has been assessed via tumor mutational burden (TMB) or mismatch repair deficiency. All of these methods have the potential to predict treatment responses to a certain extent, but are still too complex to be used in the clinical routine. A further challenge is imaging of the cancer treatment response to ICI. Tumor lesions can initially increase in size due to
inflammatory events. This pseudoprogression cannot be distinguished easily from an increase in size due to tumor growth. Consequently, the classical RECIST V.1.1 criteria were modified to the iRECIST criteria, which recommend treatment beyond the first progression. The main problem of this procedure is that patients with real tumor progression lose time for a probably more efficient radiotherapy and/or chemotherapy.

A recent strategy to complement these approaches is to analyze changes of peripheral blood immune cells at early time points during treatment. The peripheral blood immune status may have a high predictive power for the treatment response of solid tumors to ICI, as several immune cells that were already proven to predict treatment responses when being present in the tumor tissue also circulate through the peripheral blood. Furthermore, peripheral blood can be drawn easily and be repeated without an additional risk for the patients compared with repeated biopsies of the tumor tissue. Immunophenotyping (IPT) of peripheral blood from patients with stage IV melanoma before and after treatment with ICI already identified pharmacodynamic changes in circulating CD8+ T cells with an exhausted-phenotype. Clinical failure of the patients was identified to be associated with an imbalance between T-cell reinvigoration and tumor burden. Another study identified a predictive character of proliferating (Ki-67+) PD1+CD8+ T cells for the response to anti-PD-1 immunotherapy in solid tumors. Using high-dimensional single-cell mass cytometry, Krieg and colleagues identified monocytes, expressing high levels of HLA-DR to be predictive for the treatment response to anti-PD-1 therapy.

In the introduced preplanned biomarker analysis of the prospective ST-ICI cohort, the peripheral blood immune phenotype of patients with recurrent and/or metastatic cancer treated with ICI was prospectively monitored by multicolor flow cytometry. Our aim was to construct a predictive immune signature, based on the peripheral blood immunophenotype that identifies patients who benefit from ICI.

**MATERIALS AND METHODS**

**Patients**

Patients with recurrent and/or metastatic cancer with clinically indicated treatment with ICI were eligible
for this prospective non-interventional study. Patients could be included independent from cancer entity and concomitant radiotherapy. Criteria for eligibility were adult age of at least 18 years and the willingness of the patients to allow regular blood draws for immune phenotyping of peripheral blood. As the trial should represent the predominant clinical situation, there were no limitations regarding baseline Eastern Cooperative Oncology Group performance status or baseline routine blood parameters. Exclusion criteria were fertile patients who refused effective contraception during study treatment, persistent drug and/or alcohol abuse, patients not speaking German, patients in legal care and imprisoned patients.

Study design and treatments
Patients that were treated with ICI directed against programmed cell death protein 1 (PD-1) or PD-L1 were selected from the ST-ICI cohort. All ICI were indicated by the treating physician according to current guidelines and clinical standards. The following ICI were used: Nivolumab (Opdivo, Bristol-Myers Squibb, New York City, NY, USA), Pembrolizumab (Keytruda, Merck Sharp & Dohme, Kenilworth, New Jersey, USA), Atezolizumab (Tecentriq, Roche, Basel, Switzerland), Durvalumab (Imfinzi, AstraZeneca Group, Cambridge, England, UK) or Avelumab (Bavencio, Pfizer and Merck KGaA, Darmstadt, Germany). Dosing of the ICI was according to the European Medicines Agency marketing authorizations.

The research design for the identification of a predictive signature for patients with cancer treated with ICI is displayed in figure 1A. The redaction of the manuscript followed the Strengthening the Reporting of Observational Studies in Epidemiology guidelines for observational studies.

Endpoints and assessments
The primary endpoint of the here presented prospective interim analyzes was the association between changes of the patients’ peripheral blood immunophenotypes and the clinical outcomes. Main clinical outcome parameters were overall survival (OS), and progression-free survival (PFS). OS and PFS were calculated starting with the date of the first administration of the ICI. Peripheral whole blood immune phenotyping was performed before each administration of the ICI. The current analysis focused on the early immune phenotypes, namely before the first administration of the ICI (pre-ICI), and additionally to validate their potential as dynamic biomarker during treatment before the second administration of the ICI.

Multicolor flow cytometry
Whole blood samples of the patients were collected and the fresh whole blood was analyzed by multicolor flow cytometry according to our previously published and optimized IPT protocols. IPT was performed within 3 hours after the collection of whole blood. Data acquisition was performed on a Gallios Flow Cytometer (Beckman Coulter) in the standard filter configuration. The Kaluza Flow Analysis Software (Beckman Coulter) was used for data analysis. The immune cell subpopulations analyzed were visualized and specified in online supplemental figure 1.

Data collection
Differences in OS and PFS were analyzed in dependence of the absolute immune cell counts of each immune cell subset and in dependence of the clinical factors age, gender, tumor entity, PD-L1 expression (assessed by the tumor proportion score (TPS)), the number of previous treatments and the presence of brain metastases.

Development and validation of liquid immune profile-based signature
The overall workflow for the development of the liquid immune profile-based signature (LIPS) is shown in figure 1B. Univariate Cox proportional hazard regression was applied to examine the association between peripheral blood immunophenotypes and patients’ OS. Peripheral blood immune cells statistically significant associated (p<0.2) with the OS of the patients served as candidates for further analyzes. To uncover the practicability and accuracy of LIPS for patients with metastasized cancer treated with ICI, all patients were divided randomly into the training (n=56) and validation (n=33) cohorts. Least absolute shrinkage and selection operator (LASSO) could reduce the complexity of the model and can be used well with the Cox proportional hazard regression model for survival analysis with high dimensional data. The Cox-LASSO regression model was applied to develop a multi-immunophenotype-based predictive signature for OS in the training cohort. After 200,000-time steps for LASSO, the best C-index related model was selected as LIPS. Subsequently, we analyzed the data in a validation cohort for this model, to assess its feasibility and reliability in patients treated with ICI. The optimal cut-off value for the risk score (figure 2A) was determined by surv_cutpoint function in survminer package. All patients were divided into different groups (high-risk or low-risk) based on the cut-off of the risk score, which was calculated by considering the expression of immunophenotypes and the correlation coefficient. In order to validate the predictive ability of LIPS for PFS, these same coefficients of LIPS were calculated as risk score for survival analysis.

Statistical analysis
Associations between clinical characteristics in the training and the validation cohorts, or pre-ICI and after first ICI were evaluated using the χ² test. OS time was defined from the date of the first administration of the ICI to the date of the last follow-up or death of the patient. PFS time was defined from the date of the first administration of the ICI to the date of the last follow-up or first radiological confirmed progression (eg, imaging date) or date of death (whichever occurs first). The Kaplan-Meier
method and Cox proportional hazard regression models were applied to compare survival of the different groups with the immunophenotypes, LIPS and related clinical factors. Univariate, multivariate and subgroup analyzes were used to evaluate the impact of other confounding factors. Results of Cox regression analysis are described by means of HRs, 95% CI of HR and p values (Wald test). The concordance index (C-index) and the time-dependent receiver operating characteristic (ROC) curve, and the area under the ROC curve (AUC) values were calculated for different models as a measure of the discriminatory ability that allows comparison of signatures. A signature with a C-index of 0.5 has no predictive value, but the signature with a C-index of 1 would allow a perfect prediction of the patient’s outcome.

After the data cleaning steps, 54 peripheral blood immune markers were included into a univariate cox survival analysis. The following 14 of them were associated with OS (p<0.2): monocytes (CD14high), monocytes (CD14low), neutrophils, dendritic cells (DCs), myeloid (m)DCs-1, mDCs-2, plasmacytoid DCs (pDCs), natural killer (NK) cells (CD56high/CD16+), NKT cells (CD3+/CD56+/CD16+), NKT cells (CD3+/CD16+), CD8+ T cells (PD-1+), CD8+ T cells (CD25+), CD8+ T cells (CD69+), and regulatory T cells (Tregs) (Table 2).

The ST-ICI cohort was then randomly assigned to a training cohort (n=56) and a validation cohort (n=33) for further LASSO proportional hazards Cox regression analysis. After 200,000 times repeat LASSO regression, the highest C-index’s model was chosen as the LIPS. This predictive signature model obtained from the training cohort showed the following risk score=(0.00001219963×the absolute immune cell

cancer (NSCLC) in 39 patients (44%). The drugs used were Nivolumab in 58 patients (65%), Pembrolizumab in 20 patients (23%), Durvalumab in 8 patients (9%), Avelumab in 2 patients (2%), Atezolizumab in 1 patient (1%).

The ICI was first line treatment in 19 patients (21%). In the recurrent and/or metastatic setting, 13 patients (15%) had received one prior systemic treatment and 57 patients (64%) two or more prior systemic treatments. The median follow-up was 8.3 months. A total of 57 OS-events and 72 PFS-events occurred during the follow-up period. Median OS was 8.7 months, median PFS was 4.2 months.

**RESULTS**

**Patient characteristics**

A total of 104 patients were prospectively enrolled in the ST-ICI cohort between April 2017 and August 2019 (Figure 1B). Whole blood samples for IPT pre-ICI were available of 89 patients, and for 65 of these 89 patients also after first ICI. The patient characteristics are presented in Table 1 and online supplemental sTable 1. The median age was 65.8 years; 73% were men. Most frequent tumor entities were head and neck squamous cell carcinoma (HNSCC) in 40 patients (45%) and non-small cell lung

**Development and definition of the LIPS**

After the data cleaning steps, 54 peripheral blood immune markers were included into a univariate cox survival analysis. The following 14 of them were associated with OS (p<0.2): monocytes (CD14high), monocytes (CD14low), neutrophils, dendritic cells (DCs), myeloid (m)DCs-1, mDCs-2, plasmacytoid DCs (pDCs), natural killer (NK) cells (CD56high/CD16+), NKT cells (CD3+/CD56+/CD16+), NKT cells (CD3+/CD16+), CD8+ T cells (PD-1+), CD8+ T cells (CD25+), CD8+ T cells (CD69+), and regulatory T cells (Tregs) (Table 2).

The ST-ICI cohort was then randomly assigned to a training cohort (n=56) and a validation cohort (n=33) for further LASSO proportional hazards Cox regression analysis. After 200,000 times repeat LASSO regression, the highest C-index’s model was chosen as the LIPS. This predictive signature model obtained from the training cohort showed the following risk score=(0.00001219963×the absolute immune cell

**RESULTS**

**Patient characteristics**

A total of 104 patients were prospectively enrolled in the ST-ICI cohort between April 2017 and August 2019 (Figure 1B). Whole blood samples for IPT pre-ICI were available of 89 patients, and for 65 of these 89 patients also after first ICI. The patient characteristics are presented in Table 1 and online supplemental sTable 1. The median age was 65.8 years; 73% were men. Most frequent tumor entities were head and neck squamous cell carcinoma (HNSCC) in 40 patients (45%) and non-small cell lung cancer (NSCLC) in 39 patients (44%). The drugs used were Nivolumab in 58 patients (65%), Pembrolizumab in 20 patients (23%), Durvalumab in 8 patients (9%), Avelumab in 2 patients (2%), Atezolizumab in 1 patient (1%).

The ICI was first line treatment in 19 patients (21%). In the recurrent and/or metastatic setting, 13 patients (15%) had received one prior systemic treatment and 57 patients (64%) two or more prior systemic treatments. The median follow-up was 8.3 months. A total of 57 OS-events and 72 PFS-events occurred during the follow-up period. Median OS was 8.7 months, median PFS was 4.2 months.

**Development and definition of the LIPS**

After the data cleaning steps, 54 peripheral blood immune markers were included into a univariate cox survival analysis. The following 14 of them were associated with OS (p<0.2): monocytes (CD14high), monocytes (CD14low), neutrophils, dendritic cells (DCs), myeloid (m)DCs-1, mDCs-2, plasmacytoid DCs (pDCs), natural killer (NK) cells (CD56high/CD16+), NKT cells (CD3+/CD56+/CD16+), NKT cells (CD3+/CD16+), CD8+ T cells (PD-1+), CD8+ T cells (CD25+), CD8+ T cells (CD69+), and regulatory T cells (Tregs) (Table 2).

The ST-ICI cohort was then randomly assigned to a training cohort (n=56) and a validation cohort (n=33) for further LASSO proportional hazards Cox regression analysis. After 200,000 times repeat LASSO regression, the highest C-index’s model was chosen as the LIPS. This predictive signature model obtained from the training cohort showed the following risk score=(0.00001219963×the absolute immune cell
counts of neutrophils)+(-0.0335468×the absolute immune cell counts of pDCs)+(-0.08766993×the absolute immune cell counts of CD8+ T cells (PD-1+)). In this signature, neutrophils and CD8+ T cells being positive for PD-1 surface expression were positive coefficients, which means that patients with increasing absolute cell counts had a shorter OS. However, pDCs, NKT cells, CD8+ T cells (CD3+/CD56+/CD16+), and monocytes (CD14high) were negative coefficients, which means that patients with increasing absolute cell counts had a longer OS.

According to best C-index (0.74, 96% CI 0.67 to 0.82), the optimal cut-off was −0.487, which classified the training cohort into a low-risk group (n=44) and a high-risk group (n=12) (figure 2A–C).

In the training cohort, each unit increase in LIPS was associated with a 0.26-fold increase in OS rates (95% CI 0.12 to 0.56, p=0.00025). The median OS in the LIPS low-risk and high-risk groups was 14.5 (95% CI 10.1-NE (not estimable)) vs 5.4 (95% CI 3.0-NE) months, respectively (figure 3A).

The validation cohort was classified using the same cut-off of LIPS into a low-risk group (n=29) and a high-risk group (n=4) (figure 2D–F). The validation cohort confirmed the proposed risk model (C-index=0.71, 95% CI 0.62 to 0.81). The median OS in the low-risk and high-risk groups was 11.5 (95% CI 9.2 to 20.6) versus 3.7 (95% CI 2.8-NE) months (HR=0.30, 95% CI 0.10 to 0.91, p=0.024), respectively (figure 3C).

The sensitivity and specificity of LIPS for predicting the OS were plotted in a time-dependent ROC. In the training cohort, the AUC values for 6-month, 12-month, and 24-month OS prediction were 0.731, 0.716, and 0.62 to 0.81. The median OS in the low-risk and high-risk groups was 11.5 (95% CI 9.2 to 20.6) versus 3.7 (95% CI 2.8-NE) months (HR=0.28, 95% CI 0.15 to 0.52, p<0.001), respectively (figure 3A).

The time-ROC results indicate that this signature is still a powerful predictor for OS in the whole cohort (AUC2m=0.77, AUC12m=0.72, AUC24m=0.82) (figure 3B). The validation cohort, the AUC values for 6-month, 12-month, and 24-month OS prediction were 0.731, 0.716, and 0.768, respectively (figure 3D).

In the total ST-ICI cohort, the median OS in the low-risk and high-risk groups was 12.5 (95% CI 9.8 to 19.7) versus 4.7 (95% CI 3.0-NE) months (HR=0.28, 95% CI 0.15 to 0.52, p<0.001), respectively (figure 4A).

The time-ROC results indicate that this signature is still a powerful predictor for OS in the whole cohort (AUC2m=0.77, AUC12m=0.72, AUC24m=0.82) (figure 4B). Additionally, LIPS also can predict the PFS benefit for patients treated with ICI (low-risk vs high-risk: HR=0.22 (95% CI 0.12 to 0.39); the median PFS of low-risk and high-risk are 6.3 and 2.0 months, respectively (figure 4C); AUC2m=0.69, AUC12m=0.68, AUC24m=0.69 (figure 4D). These results indicate that the developed LIPS can predict which patients with cancer have a

### Table 1 Baseline characteristics of patients with metastatic cancer treated with immune checkpoint inhibitors (ICI) and for which immunophenotyping was performed pre-ICI

| Features          | Training cohort | Validation cohort | P value |
|-------------------|-----------------|-------------------|---------|
| Total             | 56              | 33                |         |
| Gender            |                 |                   | 0.5571  |
| Male              | 42 (75%)        | 23 (69.7%)        |         |
| Female            | 14 (25%)        | 10 (30.3%)        |         |
| Age               |                 |                   | 0.4133  |
| ≥60               | 16 (28.57%)     | 13 (39.39%)       |         |
| <60               | 40 (71.43%)     | 20 (60.61%)       |         |
| Tumor entity      |                 |                   | 0.8186  |
| HNSCC             | 24 (42.86%)     | 16 (48.49%)       |         |
| NSCLC             | 26 (46.42%)     | 13 (39.39%)       |         |
| others            | 6 (10.71%)      | 4 (12.12%)        |         |
| Brain metastases  |                 |                   | 0.6538  |
| Yes               | 12 (21.43%)     | 5 (15.15%)        |         |
| No                | 44 (78.57%)     | 28 (84.85%)       |         |
| PD-L1 TPS         |                 |                   | 0.8995  |
| <1%               | 19 (33.93%)     | 12 (36.37%)       |         |
| 1%-49%            | 18 (32.14%)     | 10 (30.3%)        |         |
| 50%-100%          | 17 (30.36%)     | 11 (33.33%)       |         |
| NA                | 2 (3.57%)       | 0                 |         |
| Number of previous treatments | 0.7304 |                   |         |
| 0–1               | 22 (39.29%)     | 10 (30.3%)        |         |
| ≥2                | 34 (60.71%)     | 23 (69.7%)        |         |

HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small-cell lung cancer; TPS, tumor proportion score.

### Table 2 Univariate Cox regression pre-ICI (p<0.2)

| Characteristics | HR     | 95% CI   | P value |
|-----------------|--------|----------|---------|
| Monocytes (CD14high) | 0.28   | 0.16 to 0.47 | 0       |
| Monocytes (CD14low)  | 1.37   | 1.14 to 1.66 | 0.00109 |
| Neutrophils        | 1.68   | 1.15 to 2.44 | 0.00682 |
| DCs               | 0.69   | 0.47 to 1.03 | 0.06665 |
| mDCs-1            | 0.47   | 0.27 to 0.83 | 0.00991 |
| mDCs-2            | 0.75   | 0.58 to 0.97 | 0.0258  |
| pDCs              | 0.56   | 0.4 to 0.8  | 0.00114 |
| NK cells (CD56high/CD16+) | 0.84  | 0.64 to 1.09 | 0.19433 |
| NKT cells (CD3+/CD56+/CD16+) | 0.61  | 0.4 to 0.92 | 0.01906 |
| NKT cells (CD3+/CD16+) | 0.76  | 0.58 to 1   | 0.0491  |
| CD8+ T cells (PD-1+) | 1.63   | 1.06 to 2.51 | 0.02604 |
| CD8+ T cells (CD25+) | 1.2   | 0.93 to 1.56 | 0.1591  |
| CD8+ T cells (CD69+) | 0.75   | 0.49 to 1.15 | 0.18642 |

DCs, dendritic cells; mDCs, myeloid dendritic cells; NKT cells, natural killer T cells; pDCs, plasmacytoid dendritic cells.
prolonged OS and PFS after treatment with anti-PD-1 or anti-PD-L1 in the early phase.

**Predictive role of LIPS in patients with metastatic cancer treated with ICI**

To determine whether the LIPS could serve as an independent predictive factor, Cox proportional hazard regression model was used for the detection of the relationships between OS and the clinical factors (table 3). In the ST-ICI cohort, univariate analysis showed that LIPS and brain metastases were significantly associated with OS, while multivariate analysis showed that age, PD-L1 TPS >50% and LIPS were significantly associated with OS (p<0.05).

Furthermore, LIPS, number of previous treatments and brain metastases were significantly associated with PFS in the univariate analysis; however, only LIPS was significantly associated with PFS in the multivariate analysis. These results indicate that LIPS remained an independent survival benefit predictor for patients with metastatic cancer treated with ICI.

**Applicability of LIPS in patients with cancer with different clinical characteristics**

Post-hoc subgroup analyzes based on patient characteristics suggested that OS and PFS HRs favored the LIPS low-risk group in most subgroups (figure 5, online supplemental sFigures 2–7). The LIPS had a predictive value both in PD-L1 TPS low and high cohorts (figure 5A, online supplemental sFigure 3). However, no differences of OS and PFS were found between low-risk and high-risk groups in patients with brain metastases (online supplemental sFigure 4). Median OS and PFS of patients stratified by tumor entity, age, gender, and number of previous treatments...
treatments are shown in online supplemental sFigures 2, 3, 5–7, respectively.

**NKT cells and neutrophils still predict OS and PFS when being analyzed after the first administration of the ICI**

The 14 OS-related immune cell subtypes from the pre-ICI time point, based on a Cox regression ($p<0.2$) (Table 2), were also studied in the time point after the first administration of ICI. This analysis revealed that five of them were still significantly ($p<0.05$) associated with OS (online supplemental sTable 2). The high relevance of considering the dynamics of immune cells in defining predictive signatures is highlighted in online supplemental sFigure 8. While for example, monocytes and PD-1 expressing CD8+ T cells showed a strong decrease in the peripheral blood, NKT cells were relatively stable (mean of the differences for log2(count)=0.21). These NKT cells (CD3+/CD56+/CD16+) (online supplemental sFigure 9) and neutrophils (online supplemental sFigure 10) can still be used as dynamic predictive biomarkers for OS and PFS after first administration of the ICI.

**DISCUSSION**

In recent years, ICI with or without chemotherapy were approved for multiple recurrent or metastatic cancer types. However, only approximately 20% of non-selected patients experience long-term benefit.2 24 Numerous studies suggest that TMB may predict the clinical response to ICI across multiple cancer types.25–27 However, different studies used different cut-off values based on independently companies’ database or cancer types to define low and high TMB.

The detection of PD-L1 by different methods or cut-off values could also guide anti-PD-1/PD-L1 therapy, but...
Table 3  Univariate and multivariate Cox regression analysis for overall survival and progression-free survival

| Parameter                  | Overall survival | Progression-free survival |
|---------------------------|------------------|---------------------------|
|                           | Univariate Cox regression | Multivariate regression | Univariate Cox regression | Multivariate regression | Univariate Cox regression | Multivariate regression |
|                           | HR    | 95% CI  | P value | HR    | 95% CI  | P value | HR    | 95% CI  | P value | HR    | 95% CI  | P value |
| LIPS signature            |       |         |         |       |         |         |       |         |         |       |         |         |
| High risk                 | Ref   |         |         | Ref   |         |         | Ref   |         |         | Ref   |         |         |
| Low risk                  | 0.28  | 0.15 to 0.52 | <0.001*** | 0.27  | 0.13 to 0.59 | <0.001*** | 0.22  | 0.12 to 0.39 | <0.001*** | 0.24  | 0.11 to 0.55 | <0.001*** |
| Age                       |       |         |         |       |         |         |       |         |         |       |         |         |
| <60 years                 | Ref   |         |         | Ref   |         |         | Ref   |         |         | Ref   |         |         |
| ≥60 years                 | 1.36  | 0.77 to 2.41 | 0.3 | 2.27  | 1.14 to 4.53 | 0.02* | 1.13  | 0.68 to 1.86 | 0.6 | 1.58  | 0.89 to 2.80 | 0.12 |
| Gender                    |       |         |         |       |         |         |       |         |         |       |         |         |
| Male                      | Ref   |         |         | Ref   |         |         | Ref   |         |         | Ref   |         |         |
| Female                    | 1     | 0.54 to 1.86 | 1 | 1.48  | 0.70 to 3.15 | 0.305 | 0.77  | 0.44 to 1.34 | 0.4 | 0.99  | 0.52 to 1.88 | 0.98 |
| Tumor entity              |       |         |         |       |         |         |       |         |         |       |         |         |
| Others                    | Ref   |         |         | Ref   |         |         | Ref   |         |         | Ref   |         |         |
| HNSCC                     | 0.91  | 0.54 to 1.55 | 0.7 | 0.51  | 0.21 to 1.25 | 0.142 | 1.41  | 0.88 to 2.25 | 0.1 | 0.80  | 0.34 to 1.89 | 0.618 |
| NSCLC                     | 0.94  | 0.56 to 1.59 | 0.8 | 0.56  | 0.23 to 1.40 | 0.216 | 0.7   | 0.44 to 1.12 | 0.1 | 0.55  | 0.22 to 1.36 | 0.20 |
| Brain metastases          |       |         |         |       |         |         |       |         |         |       |         |         |
| Yes                       | Ref   |         |         | Ref   |         |         | Ref   |         |         | Ref   |         |         |
| No                        | 0.43  | 0.24 to 0.79 | 0.005** | 0.56  | 0.27 to 1.17 | 0.123 | 0.46  | 0.26 to 0.80 | 0.005** | 0.85  | 0.39 to 1.89 | 0.698 |
| PD-L1 TPS                 |       |         |         |       |         |         |       |         |         |       |         |         |
| <1% / NA                  | Ref   |         |         | Ref   |         |         | Ref   |         |         | Ref   |         |         |
| 1%–49%                    | 0.69  | 0.39 to 1.24 | 0.2 | 0.61  | 0.31 to 1.22 | 0.162 | 0.61  | 0.36 to 1.02 | 0.06 | 0.57  | 0.30 to 1.10 | 0.093 |
| 50%–100%                  | 0.78  | 0.43 to 1.41 | 0.4 | 0.45  | 0.21 to 0.95 | 0.037* | 0.89  | 0.54 to 1.47 | 0.6 | 0.63  | 0.32 to 1.21 | 0.165 |
| Number of previous treatments |       |         |         |       |         |         |       |         |         |       |         |         |
| ≥2                        | Ref   |         |         | Ref   |         |         | Ref   |         |         | Ref   |         |         |
| 0–1                       | 0.60  | 0.34 to 1.08 | 0.08 | 0.79  | 0.39 to 1.59 | 0.508 | 0.49  | 0.30 to 0.82 | 0.005** | 0.63  | 0.36 to 1.11 | 0.111 |

*p<0.05, **p<0.01, ***p<0.001.
HNSCC, head and neck squamous cell carcinoma; LIPS, liquid immune profile-based signature; NSCLC, non-small cell lung cancer; TPS, tumor proportion score.
still harbors the risk of a false-negative patient stratification. The gene methylation status may also serve to select patients who will experience a clinical benefit from the PD-1 blockade. Nevertheless, there is still particular need of additional or complementary time saving, cost-effective, safe, and easy applicable tools to identify patients with cancer who could benefit from ICI.

In this context, a detailed knowledge about the immune status, both in the tumor and in the periphery, is needed to judge about the potential of cancer immunotherapy and the efficacies of immunotherapies. Tumor immunogenicity scores are under evaluation as predictors for responses to ICI. Previous studies already indicated peripheral blood immune cell subsets like PD-1+CD56+ T cells or CD4+ and CD8+ cells to be associated with favorable outcome for advanced melanoma patients treated with ipilimumab directed against cytotoxic T lymphocyte antigen-4 (CTLA-4). Now we identified a liquid immune profile-based signature to predict response of patients with metastatic cancer to anti-PD-1/PD-L1 treatment at an early time point.

To our best knowledge, the prospective ST-ICI cohort is the first one, which prospectively included a whole-blood multicolor flow cytometry-based approach for the identification of a detailed peripheral immune status in a clinical relevant multitype advanced cancer patient cohort treated with anti-PD-1/PD-L1 ICI. For these patients the treatment response according to RECIST V.1.1 is less appropriate for defining a prognostic signature. The main cohorts in ST-ICI are NSCLC and HNSCC. Pseudo-progression is a rare, but a frequently appearing phenomenon in PD-1 inhibitor therapy. These patients are rated as “progressive disease” according to RECIST V.1.1, even though they are probably the best responders later on. In NSCLC patients continuing immunotherapy beyond progression had significantly prolonged OS. The newly developed iRECIST criteria might be a method to cope with this problem, but have not been established in prospective clinical trials so far. Also, in HNSCC a secondary analysis of the CheckMate-141 trial identified responses after initial progression. A total of 24% of patients developed a reduction of the RECIST sum of diameters after initial progression. This highlights also in HNSCC that patients benefit from ICI even if tumor progression is identified in the first imaging assessment. Growing evidence indicates that there is a large number of patients that benefit from ICI also without developing an objective response according to RECIST V.1.1. Consequently, we decided to use the more valid endpoint OS for the development of our prognostic signature.

To avoid large volume blood sampling for preparation of peripheral blood mononuclear cells and to include granulocytes in the analyzes, the IPT was performed in fresh whole blood without preceding isolation of specific cells. Thus, whole blood assays gain importance as they are an easy approach to screen a large number of blood parameters. Within the ST-ICI cohort, 54 immune cell subsets were monitored in the patients with the need of less than 1 mL of peripheral whole blood. Our identified LIPS has the advantage of being easily integrated into clinical use for nominal expense. In a first step, 14 immune cell subsets were identified to be associated with OS. Furthermore, LASSO regression constructed the LIPS signature including neutrophils, pDCs, NKT cells (CD3+/CD56+/CD16+), monocytes (CD14 high), and CD8+ T cells (PD-1+). This signature includes innate and adaptive immune cells and serves as an effective tool for the identification of patients with metastatic cancer who benefit from ICI treatment. It is becoming more and more evident that multiple immune cell subsets in a concerted action may help for selecting patients that are likely to respond to ICI.

We identified that increasing amounts of neutrophils in the peripheral blood of patients with cancer were associated with decreasing OS. Figure 5 Subgroup analysis of the liquid immune profile-based signature (LIPS) predict survival benefit of patients treated with ICI by baseline characteristics. Subgroup analysis of the LIPS predict overall survival (OS) benefit (A) and progression-free survival (PFS) benefit (B) of patients treated with ICI. HR and 95% CIs. HNSCC, head and neck squamous cell carcinoma; ICI, immune checkpoint inhibitors; NSCLC, non-small cell lung cancer; TPS, tumor proportion score.
with less benefit from ICI treatment. Neutrophils have been reported to support for example the development of metastasis through multiple mechanisms, such as the release of proteases that degrade antitumor factors, and leukotrienes that propagate metastasis-initiating cells. In addition, pro-tumorigenic neutrophils suppress antitumor T cell responses. Decreased migration of neutrophils to tumor areas or the inhibition of granulocyte colony stimulating factor to decrease the amount of neutrophils has already shown efficacy in preclinical models. Recent findings suggest that neutrophil antagonism will improve the efficacy of ICI therapy in the future.

Regarding innate immune cells not of the granulocytic, but of the monocytic compartment, increased amounts of CD14 high expressing monocytes in the peripheral blood are associated with improved prognosis. This is in accordance with the findings of Krieg et al who identified CD14+/HLA-DR+ monocytes as a strong predictor of PFS and OS in response to anti-PD-1 immunotherapy in melanoma patients. We here show the importance of CD14 high expressing monocytes in the peripheral blood for non-melanoma solid tumor patients. Further, we found that increased amounts of plasmacytoid dendritic cells (pDCs) are beneficial for the PFS and OS. pDCs have a central role in activating host innate and adaptive immune responses and they are known as the major interferon type I-producing cells. Thereby, pDCs activate many other cell types, such as monocytes, NK cells, and T cells which are known to be also crucial for antitumor immune responses. High levels of circulating pDCs were already found to predict a favorable outcome in patients with breast cancer and for patients with pancreatic adenocarcinoma.

NKT cells are suggested to induce a cross talk of pDCs with conventional DCs that result in induction of memory CD8+ T cells. We identified increased numbers of CD8+ T cells in patients of the ST-ICI cohort to be favorable for PFS and OS. Just recently, it was shown for patients with NSCLC that increased amounts of peripheral NK cells correlate with responses to anti-PD-1 treatment. The role for NKT cells in this scenario has not been investigated before, but it is becoming more and more evident that NKT cells are important in antitumor immunity as they, for example, reinvigorate exhausted immune cells in the tumor microenvironment.

Exhausted immune cells fail to contribute to antitumor immunity. Increased numbers of PD-L1+ NK cells in the peripheral blood, for example, are associated with poor response to anti-PD-1 treatment of patients with NSCLC. However, intratumoral CD8+ T cells which are positive for PD-1+ were shown to be predictive for response and survival on anti-PD-1 antibody therapy, as shown in a small cohort of patients with NSCLC. Studies in chronic myeloid leukemia patients just recently revealed that differences in PD-1. Expression on CD8+ T-cells might predict the disease course. Our immune monitoring suggests that increased amounts of circulating PD-1+ CD8+ T cells at early time points of ICI therapy predict a poorer OS and PFS in patients with metastatic solid tumors treated with ICI. This might indicate that in these cases the activated CD8+ T cells cannot enter properly into the tumor and exert their antitumor activity.

The ST-ICI cohort has been a clinically highly relevant group of advanced stage patients with solid tumors, that includes some confounding factors such as the treatment with different ICI, different tumor types, brain metastases, the number of previous treatments and PD-L1 expression. La and colleagues identified a median OS of NSCLC patients of 9.9 months in the second line ICI treatment, and a median OS of HNSCC patients of 7.4 months in real-world cohorts. This is in line with our findings with a median OS of 8.7 months in a cohort consisting mainly of NSCLC and HNSCC. In the ST-ICI cohort, 32 patients had 0–1 previous treatments, while 57 patients had ≥ 2 of previous treatments. Patients with less (0–1) of previous treatments did not show significantly prolonged OS (HR=0.60 (0.34-1.08), median OS(0–1)=12.46 (9.76-NE) months, median OS(≥ 2)=9.44 (7.43–14.5) months), but a prolonged PFS (HR=0.49 (0.30-0.82), median PFS(0–1)=7.79 (4.01–15.88) months, median PFS(≥ 2)=3.22 (2.93–5.79) months). Furthermore, number of previous treatments (0–1 vs ≥ 2) was significantly associated with PFS in the univariate analysis, however, it was not significantly associated with PFS in the multivariate analysis. The number of previous treatments was also not significantly associated with OS in the univariate and multivariate analysis. Taken together, this factor did not impact our LIPS signature as predictor for ICI. The multivariable Cox regression and subgroup analyzes suggest that LIPS is an independent predictive factor for patients with advanced cancer treated with ICI targeting the PD-1/PD-L1 axis. The subgroup analyzes suggest that this immune signature can reliably predict OS and PFS benefit for patients with cancer treated with ICI in any subgroups, except for brain metastases. This may be a consequence of a continuous administration of glucocorticoids in these patients. Although patients with brain metastases can benefit from ICI treatment, the knowledge about the immune microenvironment at this tumor location side is scarce, and future trials will have to particularly focus on this subgroup of the ST-ICI study population.

In present clinical practices, PD-L1 expression is an essential biomarker as drug approvals mostly depend on its expression. However, our subgroup analyzes revealed that the LIPS predicts survival benefits independent from PD-L1 expression. Notably, LIPS identified more than 82% of all patients with advanced cancer, who benefit from anti-PD-1/ PD-L1 antibodies.

It has been recognized that a non-invasive and early detection of multiple parameters including peripheral immune features are promising to predict the clinical response of patients with cancer to ICI. At the same time, the dynamics of the responses should be considered. As the NKT cells and neutrophils as central part of our identified LIPS can still predict OS and PFS even after the first administration of the ICI (online supplemental sFigures 9–10), our analyzes and results demonstrate that easy applicable immune phenotyping of peripheral blood of patients with metastasized cancer allows an accurate and early forecasting of OS and PFS in patients with metastatic cancer.
CONCLUSION
Our prospective analyzes of the immune status of patients of the ST-ICI cohort demonstrated that LIPS can predict which patients with cancer with advanced disease will benefit from ICI treatment and therefore could guide clinical decisions in patients with recurrent and/or metastatic cancer treated with ICI.

Author affiliations
1Department of Radiation Oncology, Universitätsklinikum Erlangen, Erlangen, Germany
2Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany
3Department of Oncology, The Second Affiliated Hospital of Zunyi Medical University, Zunyi, China
4Institute of Pathology, Universitätsklinikum Erlangen, Erlangen, Germany
5Department of Radiation Oncology, Gustave Roussy - CentraleSupélec - TheraPanacea Center of Artificial Intelligence in Radiation Therapy and Oncology, Villejuif, France
6Université Paris-Saclay, INSERM1030 Radiothérapie Moléculaire, Villejuif, France

Twitter Jian-Guo Zhou @JianGGuoZhou3, Benjamin Frey @BetterCallBenni, Markus Eckstein @MarkusEckstein3, Roger Sun @grsund and Udo Gaipi @GaipiS

Acknowledgements
The authors thank the patients who participated in the study, their supporters, the investigators, and clinical research staff from the Department of Radiation Oncology. The present work was performed by J-G in (partial) fulfillment of the requirements for containing the degree “Dr. rer. biol. hum.”. We further acknowledge the support by the German Research Foundation and the Friedrich-Alexander-Universität Erlangen-Nürnberg within the funding program Open Access Publishing.

Contributors
Conception and design: MH, UG, BF, RF, HM, J-G, ME, A-JD. Development of methodology: J-G, A-JD. Acquisition of data: A-JD, SR, IB, BF, ME, MH, UG. Analysis and interpretation of data: J-G, AD, ED, RS, PS, UG, MH. Writing, review, and/or revision of the manuscript: J-G, A-JD, RF, MH, UG, ED, RS, CS, PS. Administrative, technical, or material support: SR, CS, HM. Study supervision: UG, MH, RF, BF.

Funding
The study was supported by the Department of Radiation Oncology, Universitätsklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany and it was partly supported by the BMBF (GREGIS-alpha, 02NUK050E), and the NSFC (Grant No. 82060475).

Competing interests
MH reports conflict of interest with Merck Serono (advisory boards, honoraria for lectures, travel grants, research funding); MSD (advisory boards, travel grants, research funding); AstraZeneca (research funding; Novartis (research funding); BMS (advisory boards, honoraria for lectures); Teva (travel grants). UG received support for presentation activities for Dr Sennewald Medizintechnik GmbH, has received support for investigator initiated clinical studies (ITIs) from MSD and AstraZeneca and contributed at Advisory Boards Meetings of AstraZeneca and Bristol-Myers Squibb. JGZ received support from AstraZeneca (travel grants). HM reports conflict of interest with Merck Serono (advisory boards, honoraria for lectures, travel grants); MSD (advisory boards, honoraria for lectures, travel grants); AstraZeneca (advisory boards, honoraria for lectures, travel grants); BMS (advisory boards, honoraria for lectures, travel grants); Roche (honoraria, travel expenses); MSD (honoraria, speakers’ bureau); AstraZeneca (honoraria, advisory role, speakers’ bureau, travel expenses); Roche (honoraria, travel expenses); MSD (honoraria, speakers’ bureau); Aelier (honoraria, travel expenses); GenomicHealth (honoraria, advisory role, speakers’ bureau, travel expenses); AbbVie (honoraria, travel expenses); Fresenius (honoraria); BrainLAB (honoraria); AstraZeneca (honoraria, advisory role, research funding, travel expenses); Merck Serono (advisory role, research funding, travel expenses); Novocure (advisory role, speakers’ bureau, travel funding); Sennewald (speakers’ bureau, travel expenses).

Patient consent for publication
Not required.

Ethics approval
The institutional review board at the Friedrich-Alexander-Universität Erlangen-Nürnberg approved the study (number: 2_17 B). The study was performed in accordance with the Declaration of Helsinki. All patients gave written informed consent before enrollment that comprised a data privacy clause for data collection and analysis for research purpose.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
Data are available in public, open access repository. The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Jian-Guo Zhou http://orcid.org/0000-0002-5021-3739
Benjamin Frey http://orcid.org/0000-0001-6743-3351
Markus Eckstein http://orcid.org/0000-0001-5418-3349
Roger Sun http://orcid.org/0000-0001-9866-6449
Udo Gaipi http://orcid.org/0000-0001-6375-5476
Markus Hecht http://orcid.org/0000-0003-2082-216X

REFERENCES
1 Das S, Johnson DB. Immune-Related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer 2019;7:306.
2 Burtenshaw B, Harrington KJ, Greil R, et al. KEYNOTE-048: phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC). Annals of Oncology 2018;29:viii729.
3 Mok TSK, Wu Y-L, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 2019;393:1819–30.
4 Derer A, Spiljar M, Bäuml M. Chemoradiation increases PD-L1 expression in certain melanoma and glioblastoma cells. Front Immunol 2016;7.
5 Hecht M, Böttner-Herold M, Erlenbach-Wünsch K, et al. PD-L1 is upregulated by radiochemotherapy in rectal adenocarcinoma patients and associated with a favourable prognosis. Eur J Cancer 2016;65:52–60.
6 Hopkins AM, Rowland A, Kichenadasse G, et al. Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. Br J Cancer 2017;117:913–20.
7 Zaretsky JM, Garcia-Díaz A, Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med 2016;375:819–29.
8 Vokes NI, Liu D, Ricciuti B. Harmonization of tumor mutational burden quantification and association with response to immune checkpoint blockade in non-small-cell lung cancer. JCO Precis Oncol 2019;3. doi:10.1200/PO.19.00171. [Epub ahead of print: 12 Nov 2019].
9 Le DT, Uram JN, Wang H, et al. Pd-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 2015;372:2509–20.
10 Chai LF, Prince E, Pillarisetty VG, et al. Challenges in assessing solid tumor responses to immunotherapy. Cancer Gene Ther 2020;27:528–38.
Seymour L, Bogarts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 2017;18:143–52.

Zhang H, Houghton AM. Good cops turn bad: the contribution of neutrophils to immune-checkpoint inhibitor treatment failures in cancer. Pharmacol Ther 2021;217:107662.

Chen JA, Ma W, Yuan J, et al. Translational biomarkers and rationale strategies to overcome resistance to immune checkpoint inhibitors in solid tumors. Cancer Treat Rev 2020;180:251–79.

Zhang AC, Postow MA, Orlowksi RJ, et al. T-Cell invigoration to tumour burden ratio associated with anti-PD-1 response. Nature 2017;545:60–5.

Kim KH, Cho J, Ku BM, et al. The First-week Proliferative Response of Peripheral Blood PD-1+CD8+ T Cells Predicts the Response to Anti-PD-1 Therapy in Solid Tumors. Clin Cancer Res 2019;25:2144–54.

Krieg C, Nowicka M, Gulgilleta S, et al. High-Dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy. Nat Med 2018;24:144–53.

Rühle PF, Fietkau R, Gaip US, et al. Development of a modular assay for detailed immunophenotyping of peripheral human whole blood samples by multicolor flow cytometry. Int J Mol Sci 2016;17:3161.

Donaubauer A-J, Rühle PF, Becker I. One-Tube Multicolor Flow Cytometry as a Platform for Comprehensive Immunophenotyping of Peripheral Blood. In: Steinitz M, ed. Human monoclonal antibodies: methods and protocols. New York, NY: Springer New York, 2019: 189–212.

Simon N, Friedman J, Hastie T, et al. Regularization paths for COX's proportional hazards model via coordinate descent. J Stat Softw 2011;39:1–13.

Zhou J-G, Zhao H-T, Jin S-H, et al. Identification of a RNA-seq-based signature to improve prognostics for uterine sarcoma. Gynecol Oncol 2019;155:449–507.

Zhou J-G, Liang B, Jin S-H, et al. Development and validation of an RNA-Seq-Based prognostic signature in neuroblastoma. Front Oncol 2019;9:1361.

Brentnall AR, Cuzick J. Use of the concordance index for predictors of censored survival data. Stat Methods Med Res 2018;27:2359–73.

Halbe-Kains C, Reymedt C, Otisiou C, et al. A comparative study of survival models for breast cancer prognosis based on microarray data: does a single gene beat them all? Bioinformatics 2008;24:2200–8.

Ozoy RS, Bang J, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-101): a randomised controlled trial. Lancet 2016;387:1540–50.

Wang Z, Duan J, Cai S, et al. Assessment of blood tumor immunologic burden as a predictive biomarker for immunotherapy in patients with non-small cell lung cancer with use of a next-generation sequencing cancer gene panel. JAMA Oncol 2019;5:696–702.

Samstein RM, Lee C-H, Shoushtari AN, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 2019;51:202–6.

Hellmann MD, Nathanson T, Rizvi H, et al. Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer. Cancer Cell 2018;33:843–52.

Takada K, Toyokawa G, Okamoto T, et al. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients. Clin Lung Cancer 2017;18:572–82.

Lee H-H, Wang Y-N, Xia W, et al. Removal of N-linked glycosylation enhances PD-L1 detection and predicts anti-PD-1/PD-L1 therapeutic efficacy. Cancer Cell 2019;36:168–78.

Okuma Y, Wakui H, Utsumi H, et al. Soluble programmed cell death ligand 1 as a novel biomarker for nivolumab therapy for non-small-cell lung cancer. Clin Lung Cancer 2018;19:410–7.

Duruiseaux M, Martinez-Cardas A, Calleja-Cervantes ME, et al. Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. Lancet Respir Med 2018;6:771–81.

Gnjatic S, Bronte V, Brunet LR, et al. Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer 2017;5:44.

Wang S, He Z, Wang X, et al. Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction. Elife 2019;8:8.

Bochem J, Zelba H, Amari T, et al. Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade. PLoS One 2019;14:e0221301.

Martens A, Wistuba-Hamprecht K, Yuan J, et al. Increases in absolute lymphocytes and circulating CD4+ and CD8+ T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab. Clin Cancer Res 2016;22:4848–58.

Liang H, Xu Y, Chen M, et al. Patterns of response in metastatic NSCLC during PD-1 or PD-L1 inhibitor therapy: comparison of the RECIST 1.1 and iRECIST criteria. Thorac Cancer 2020;11:1068–75.

Haddad R, Blumenschein G, Fayett J, et al. Treatment beyond progression with nivolumab in patients with recurrent or metastatic (r/m) squamous cell carcinoma of the head and neck (SCCHN) in the phase 3 checkmate 141 study: a biomarker analysis and updated clinical outcomes. Annals of Oncology 2017;28:372–3.

Petitprez F, Meylan M, de Reyniès A, et al. The tumor microenvironment in the response to immune checkpoint blockade therapies. Front Immunol 2020;11:784.

Tüting T, de Visser KE, Ked V. Cancer. How neutrophils promote metastasis. Science 2016;352:145–6.

Ocana A, Nieto-Jiménez C, Pandiella A, et al. Neutrophils in cancer: prognostic role and therapeutic strategies. Mol Cancer 2017;16:137.

Koucký V, Bouček J, Fialová A. Immunology of plasmacytoid dendritic cells in solid tumors: a brief review. Cancers 2019;11:470.

Kini Bailur, J, Gueckel B, Pawelec G. Prognostic impact of high levels of circulating plasmacytoid dendritic cells in breast cancer. Transl Med 2016;14:151.

Tjomsland V, Sandström P, Spånges A, et al. Pancreatic adenocarcinoma exerts systemic effects on the peripheral blood myeloid and plasmacytoid dendritic cells: an indicator of disease severity? BMC Cancer 2010;10:87.

Shimizu K, Asakura M, Shinga J, et al. Invariant NKT cells induce plasmacytoid dendritic cell (dC) cross-talk with conventional DCs for efficient memory CD8+ T cell induction. J Immunol 2013;190:5609–19.

Youn J-L, Park S-M, Park J, et al. Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer. Sci Rep 2020;10:9050.

Bae E-A, Seo H, Kim I-K, et al. Roles of NKT cells in cancer immunotherapy. Arch Pharm Res 2019;42:543–8.

Julia EP, Mandó P, Rizzo MM, et al. Peripheral changes in immune cell populations and soluble mediators after anti-PD-1 therapy in non-small cell lung cancer and renal cell carcinoma patients. Cancer Immunol Immunother 2019;68:1585–96.

Thommen DS, Koezler VH, Herzig P, et al. A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade. Nat Med 2018;24:994–1004.

Lee MY, Park C-J, Cho Y-U, et al. Differences in PD-1 expression on CD8+ T-cells in chronic myeloid leukemia patients according to disease phase and TK1 medication. Cancer Immunol Immunother 2020;69:2223–232.

La J, Cheng D, Brophy MT, et al. Real-World outcomes for patients treated with immune checkpoint inhibitors in the Veterans Affairs system. JCO Clin Cancer Inform 2020;4:918–28.

Di Giacomo AM, Valente M, Cerase A, et al. Immunotherapy of brain metastases: breaking a “dogma”. J Exp Clin Cancer Res 2019;38:419.

Schmidberger H, Rapp M, Ebersberger A, et al. Long-Term survival of patients after ipilimumab and hypofractionated brain radiotherapy for brain metastases of malignant melanoma: sequence matters. Strahlenther Onkol 2018;194:1144–51.

Kocher M, Ruge M, Gallikis N, et al. Applications of radiomics and machine learning for radiotherapy of malignant brain tumors. Strahlenther Onkol 2020;196:855–67.

Nabel BY, Esfahani MS, Moding EJ, et al. Noninvasive early identification of therapeutic benefit from immune checkpoint inhibition. Cell 2020;183:363–76.
Table 1. Baseline characteristics of ICI treated metastatic cancer patients for which immunophenotyping was performed pre-ICI and after first ICI.

| Features                  | Pre-ICI | After first ICI | P-value |
|---------------------------|---------|-----------------|---------|
| **Total**                 | 89      | 65              |         |
| **Gender**                |         |                 | 0.1495  |
| Male                      | 65 (73.03%) | 50 (76.92%)    |         |
| Female                    | 24(26.97%) | 15(23.08%)     |         |
| **Age**                   |         |                 | 0.1167  |
| >=60                      | 29(32.58%) | 21(32.31%)     |         |
| <60                       | 60(67.42%) | 44(67.69%)     |         |
| **Tumor entity**          |         |                 | 0.6233  |
| HNSCC                     | 40(44.94%) | 29(44.62%)     |         |
| NSCLC                     | 39(43.82%) | 31(47.69%)     |         |
| others                    | 10(11.24%) | 5(7.69%)       |         |
| **Brain metastases**      |         |                 | 0.05829 |
| Yes                       | 17(19.1%)  | 14(21.54%)     |         |
| No                        | 72(80.9%)  | 51(78.46%)     |         |
| **PD-L1 TPS**             |         |                 | 0.9467  |
| <1%                       | 31(34.83%) | 23(35.38%)     |         |
| 1-49%                     | 28(31.46%) | 20(30.77%)     |         |
| 50%-100%                  | 28(31.46%) | 21(32.31%)     |         |
| NA                        | 2(2.25%)   | 1(1.54%)       |         |
| **Number of previous treatments** |      |                 | 0.1317  |
| 0-1                       | 32 (35.96%) | 23 (35.38%)    |         |
| ≥2                        | 57(64.04%)  | 42(64.62%)     |         |
A. HNSCC OS

| Number at risk | 0  10  20  30 |
|----------------|---------------|
| low risk       | 7  2  0  0    |
| high risk      | 33 11 5 1     |

| Number of censoring | 0  10  20  30 |
|---------------------|---------------|
| low risk            | 1             |
| high risk           | 1             |

HR 0.39 (95%CI 0.15-1.03)
low risk: median 12.89 months [95%CI 9.30-NE]
high risk: median 4.34 months [95%CI 2.99-NE]

B. NSCLC OS

| Number at risk | 0  10  20  30 |
|----------------|---------------|
| low risk       | 8  1  0  0    |
| high risk      | 31 18 3 1     |

| Number of censoring | 0  10  20  30 |
|---------------------|---------------|
| low risk            | 1             |
| high risk           | 1             |

HR 0.19 (95%CI 0.07-0.47)
low risk: median 14.47 months [95%CI 10.98-NE]
high risk: median 5.44 months [95%CI 4.18-NE]

C. HNSCC PFS

| Number at risk | 0  10  20  30 |
|----------------|---------------|
| low risk       | 7  0  0  0    |
| high risk      | 33 6 2 1      |

| Number of censoring | 0  10  20  30 |
|---------------------|---------------|
| low risk            | 1             |
| high risk           | 1             |

HR 0.34 (95%CI 0.14-0.82)
low risk: median 3.91 months [95%CI 3.09-8.09]
high risk: median 2.99 months [95%CI 0.69-NE]

D. NSCLC PFS

| Number at risk | 0  10  20  30 |
|----------------|---------------|
| low risk       | 8  0  0  0    |
| high risk      | 31 11 2 1     |

| Number of censoring | 0  10  20  30 |
|---------------------|---------------|
| low risk            | 1             |
| high risk           | 1             |

HR 0.12 (95%CI 0.05-0.32)
low risk: median 8.81 months [95%CI 6.41-14.50]
high risk: median 2.04 months [95%CI 1.36-NE]

HR 0.19 (95%CI 0.07-0.47)
low risk: median 14.47 months [95%CI 10.98-NE]
high risk: median 5.44 months [95%CI 4.18-NE]
Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
placed on this supplemental material which has been supplied by the author(s)

doi: 10.1136/jitc-2020-001845:e001845. 9 2021; J Immunother Cancer, et al. Zhou J-G
A. No brain metastases OS

- Log-rank $p < 0.0001$
- HR 0.18 (95% CI 0.08-0.41)
  - Low risk: median 12.89 months [95% CI 10.98-20.7]
  - High risk: median 4.26 months [95% CI 2.01-NE]

B. Brain metastases OS

- Log-rank $p = 0.77$
- HR 0.85 (95% CI 0.29-2.47)
  - Low risk: median 3.98 months [95% CI 2.89-NE]
  - High risk: median 6.10 months [95% CI 2.99-NE]

C. No brain metastases PFS

- Log-rank $p < 0.0001$
- HR 0.10 (95% CI 0.05-0.22)
  - Low risk: median 6.58 months [95% CI 4.77-11]
  - High risk: median 1.28 months [95% CI 0.69-NE]

D. Brain metastases PFS

- Log-rank $p = 0.72$
- HR 1.21 (95% CI 0.43-3.43)
  - Low risk: median 2.40 months [95% CI 1.84-NE]
  - High risk: median 3.09 months [95% CI 2.79-NE]
A. age < 60yr OS

HR 0.16 (95%CI 0.05-0.48)  
low risk: median 19.66 months [95%CI 9.07-NE]  
high risk: median 5.03 months [95%CI 2.99-NE]

B. age ≥ 60yr OS

HR 0.30 (95%CI 0.13-0.67)  
low risk: median 11.38 months [95%CI 9.44-19.20]  
high risk: median 4.18 months [95%CI 2.01-NE]

C. age < 60yr PFS

HR 0.25 (95%CI 0.09-0.68)  
low risk: median 7.43 months [95%CI 3.58-NE]  
high risk: median 2.99 months [95%CI 1.35-NE]

D. age ≥ 60yr PFS

HR 0.17 (95%CI 0.08-0.37)  
low risk: median 6.02 months [95%CI 3.85-9.11]  
high risk: median 1.81 months [95%CI 1.22-NE]
A. Male OS

- High risk: median 19.66 months [95% CI 8.12-NE]
- Low risk: median 5.85 months [95% CI 2.99-NE]
- HR 0.28 (95% CI 0.09-0.90)

B. Female OS

- High risk: median 19.66 months [95% CI 8.12-NE]
- Low risk: median 4.34 months [95% CI 1.84-NE]
- HR 0.28 (95% CI 0.09-0.90)

C. Male PFS

- High risk: median 5.79 months [95% CI 2.99-NE]
- Low risk: median 2.24 months [95% CI 1.35-NE]
- HR 0.22 (95% CI 0.11-0.44)

D. Female PFS

- High risk: median 7.76 months [95% CI 3.91-NE]
- Low risk: median 1.84 months [95% CI 1.36-NE]
- HR 0.22 (95% CI 0.07-0.70)
**Table 2. Univariate Cox regression before second ICI.**

| Characteristics                        | HR   | 95% CI     | P Value  |
|----------------------------------------|------|------------|----------|
| Monocytes (CD14<sup>high</sup>)        | 1.21 | 0.49 - 3.03 | 0.67945  |
| Monocytes (CD14<sup>low</sup>)         | 1.7  | 1.26 - 2.3  | 0.00046  |
| Neutrophils                            | 1.68 | 1.02 - 2.78 | 0.04192  |
| DCs                                    | 0.79 | 0.56 - 1.11 | 0.16808  |
| mDCs-1                                 | 0.45 | 0.15 - 1.32 | 0.14538  |
| mDCs-2                                 | 0.57 | 0.38 - 0.85 | 0.00606  |
| pDCs                                   | 0.62 | 0.37 - 1.04 | 0.06997  |
| NK cells (CD56<sup>high</sup>/CD16<sup>+</sup>) | 1.02 | 0.8 - 1.31  | 0.8612   |
| NKT cells (CD3<sup>+</sup>/CD56<sup>+</sup>/CD16<sup>+</sup>) | 0.35 | 0.16 - 0.75  | 0.00735  |
| NKT cells (CD3<sup>+</sup>/CD16<sup>+</sup>) | 0.12 | 0.02 - 0.66  | 0.01513  |
| CD8<sup>+</sup> T cells (PD-1<sup>+</sup>) | 1.31 | 0.83 - 2.08  | 0.24879  |
| CD8<sup>+</sup> T cells (CD25<sup>+</sup>) | 0.91 | 0.62 - 1.33  | 0.62385  |
| CD8<sup>+</sup> T cells (CD69<sup>+</sup>) | 0.62 | 0.37 - 1.05  | 0.07321  |
| T<sub>regs</sub>                        | 0.8  | 0.6 - 1.07  | 0.13725  |
**A** Monocytes (CD14high)

- Log2 (Count)
- P-value <0.0001
- Mean of the differences = 1.88

**B** CD8+ T cells (PD-1+)

- Log2 (Count)
- P-value <0.0001
- Mean of the differences = 2.15

**C** pDCs

- Log2 (Count)
- P-value <0.0001
- Mean of the differences = 1.07

**D** Neutrophils

- Log2 (Count)
- P-value <0.0001
- Mean of the differences = 3.74

**E** NKT cells (CD3+/CD56+/CD16+)

- Log2 (Count)
- P-value <0.0001
- Mean of the differences = 0.21
**Supplemental material**

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance on the information herein or any supplemental material which has been supplied by the author(s)

Zhou J-G, et al. *J Immunother Cancer* 2021;9:e001845. doi: 10.1136/jitc-2020-001845
A. Neutrophils Pre-ICI OS

Log-rank p = 0.00023

Survival probability

Month

Number at risk

Strata

low level:

high level:

Number of censoring

n.censor

B. Neutrophils Pre-ICI PFS

Log-rank p = 0.00023

Survival probability

Month

Number at risk

Strata

low level:

high level:

Number of censoring

n.censor

C. Neutrophils After first ICI OS

Survival probability

Month

Number at risk

Strata

low level:

high level:

Number of censoring

n.censor

D. Neutrophils After first ICI PFS

Survival probability

Month

Number at risk

Strata

low level:

high level:

Number of censoring

n.censor

HR 2.86 (95%CI 1.59 -5.12)

HR 2.14 (95%CI 1.25-3.66)

HR 0.44 (95%CI 0.24 -0.82)

HR 2.08 (95%CI 1.20 -3.60)

low level:

median 11.93 months [95%CI 10.06-20.60]

median 5.79 months [95%CI 3.72-8.81]

median 14.47 months [95%CI 11.47-NE]

median 7.43 months [95%CI 4.01-11.44]

high level:

median 4.26 months [95%CI 2.79-NE]

median 2.89 months [95%CI 5.03-5.85]

median 9.07 months [95%CI 5.03-11.90]

median 3.32 months [95%CI 2.73-6.02]

HR 2.86 (95%CI 1.59 -5.12)

HR 2.14 (95%CI 1.25-3.66)

HR 0.44 (95%CI 0.24 -0.82)

HR 2.08 (95%CI 1.20 -3.60)

low level:

median 11.93 months [95%CI 10.06-20.60]

median 5.79 months [95%CI 3.72-8.81]

median 14.47 months [95%CI 11.47-NE]

median 7.43 months [95%CI 4.01-11.44]

high level:

median 4.26 months [95%CI 2.79-NE]

median 2.89 months [95%CI 5.03-5.85]

median 9.07 months [95%CI 5.03-11.90]

median 3.32 months [95%CI 2.73-6.02]